Equities Analysts Set Expectations for HRMY FY2026 Earnings

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY - Free Report) - Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for shares of Harmony Biosciences in a research report issued to clients and investors on Monday, June 9th. Cantor Fitzgerald analyst P. Stavropoulos expects that the company will post earnings of $3.21 per share for the year. Cantor Fitzgerald has a "Strong-Buy" rating on the stock. The consensus estimate for Harmony Biosciences' current full-year earnings is $2.43 per share.

HRMY has been the subject of several other research reports. UBS Group reduced their price target on shares of Harmony Biosciences from $55.00 to $48.00 and set a "buy" rating for the company in a report on Monday, April 28th. HC Wainwright restated a "buy" rating and issued a $70.00 price target on shares of Harmony Biosciences in a report on Tuesday, April 8th. Mizuho boosted their price target on shares of Harmony Biosciences from $44.00 to $48.00 and gave the company an "outperform" rating in a report on Thursday, May 15th. Needham & Company LLC restated a "buy" rating and issued a $49.00 price target on shares of Harmony Biosciences in a report on Tuesday, May 6th. Finally, Oppenheimer started coverage on shares of Harmony Biosciences in a report on Monday, June 2nd. They issued an "outperform" rating and a $61.00 price target for the company. Eight analysts have rated the stock with a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company currently has a consensus rating of "Buy" and an average target price of $53.00.

Harmony Biosciences Trading Down 1.1%

Harmony Biosciences stock traded down $0.36 during trading hours on Wednesday, hitting $32.97. The company had a trading volume of 786,752 shares, compared to its average volume of 623,932. The firm has a market cap of $1.89 billion, a P/E ratio of 15.63, a P/E/G ratio of 0.47 and a beta of 0.87. The company has a debt-to-equity ratio of 0.28, a quick ratio of 3.20 and a current ratio of 3.24. Harmony Biosciences has a 1 year low of $26.47 and a 1 year high of $41.61. The company has a 50-day moving average price of $32.24 and a two-hundred day moving average price of $34.06.

Harmony Biosciences (NASDAQ:HRMY - Get Free Report) last released its quarterly earnings data on Tuesday, May 6th. The company reported $0.78 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.59 by $0.19. The company had revenue of $184.73 million during the quarter, compared to analysts' expectations of $184.26 million. Harmony Biosciences had a net margin of 17.98% and a return on equity of 23.16%. The firm's quarterly revenue was up 19.5% on a year-over-year basis. During the same period in the previous year, the company earned $0.67 EPS.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of HRMY. Deep Track Capital LP bought a new position in shares of Harmony Biosciences during the 4th quarter worth approximately $49,894,000. Vanguard Group Inc. raised its stake in shares of Harmony Biosciences by 36.4% during the 4th quarter. Vanguard Group Inc. now owns 4,733,609 shares of the company's stock worth $162,883,000 after acquiring an additional 1,262,362 shares in the last quarter. Marshall Wace LLP increased its stake in Harmony Biosciences by 165.2% during the 4th quarter. Marshall Wace LLP now owns 929,744 shares of the company's stock valued at $31,992,000 after purchasing an additional 579,103 shares in the last quarter. New Vernon Capital Holdings II LLC increased its stake in Harmony Biosciences by 3,219.0% during the 1st quarter. New Vernon Capital Holdings II LLC now owns 488,424 shares of the company's stock valued at $16,211,000 after purchasing an additional 473,708 shares in the last quarter. Finally, Norges Bank acquired a new position in Harmony Biosciences during the 4th quarter valued at approximately $16,118,000. Institutional investors own 86.23% of the company's stock.

Harmony Biosciences Company Profile

Harmony Biosciences Holdings, Inc, a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare and other neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy.